Mark is a healthcare policy and public affairs specialist, having spent nearly 20 years in-house at leading biopharma companies Bristol-Myers Squibb, Novartis and, most recently, Gilead. He has led public affairs teams in the UK, Brussels and across EMEA markets, advising country and international leadership teams on the political environment, public policy positioning, political engagement, campaigning, partnership development, stakeholder management and corporate communications.
Mark has supported the national and international launches of some of the most innovative medicines of recent years, leveraging policy, public affairs and stakeholder engagement to drive major healthcare budget allocations and successful pricing and reimbursement outcomes.
In particular, Mark has led stakeholder engagement strategies supporting NICE and SMC appraisals in the UK for a number of leading innovative medicines and he has been heavily involved in industry-wide efforts to shape the evolution of HTA policies and processes. His expertise is in mobilising advocacy from within the healthcare policy community to ensure that patients get access to the treatments they need and that the value of those treatments is fully recognised.
Mark’s experience spans multiple therapy areas including infectious diseases, cancer, cardiovascular disease, mental health and ophthalmology.